Amniotic membrane placed on the eye after crosslinking for progressive keratoconus
Tests an amniotic membrane after crosslinking for pain and healing in progressive keratoconus.
Key facts
- Who runs it
- TBF Genie Tissulaire
- Where
- France9 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 116 people, planned
- Started
- 25 Nov 2024
- Planned end
- Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Therapeutic lens alone
- Therapeutic lens + amniotic membrane (Visio-AMTRIX)
- Record updated
- 11 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with progressive keratoconus who are due to have accelerated conventional crosslinking. It tests whether an amniotic membrane placed on the eye after crosslinking reduces pain and helps the cornea heal.
- Age
- 18 to 65 years
- Sex
- Men and women
- Disease stage
- Progressive keratoconus: Kmax increase of ≥ 0.5 diopters in 3 to 6 months, or ≥ 1 diopter in 3 to 12 months with loss of 10 microns on minimum pachymetry in 3 to 12 months. Kmax ≥ 47.0 diopters (D) and inferior-superior difference of 1.5 D. Minimum corneal thickness greater than 400 microns.
- Earlier treatment
- Must not have had crosslinking, refractive eye surgery or an intracorneal ring segment in either eye. No topical cyclosporine in the last 6 months. No long-term pain medicines or corticosteroids.
Main reasons for not taking part
- Pregnant or breastfeeding, or a woman without effective contraception
- Serious autoimmune or immune-weakening disease, or a psychiatric illness
- Central clouding of the cornea, severe dry eye or neurotrophic keratitis
- Past eye herpes or eye varicella-zoster infection
- Glaucoma
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Man or woman between 18 and 65 years old
- Indication for accelerated conventional crosslinking
- Patient with progressive keratoconus (increase in Kmax of ≥ 0.5 diopters in 3 to 6 months or ≥ 1 diopter in 3 to 12 months with loss of 10 microns on minimum pachymetry in 3 to 12 month)
- Patient suffering from keratoconus with a compatible topographic form (Kmax ≥ 47.0 diopters (D) and difference inferior-superior of 1.5 D)
- Patient with a minimum corneal thickness greater than 400 microns
- Informed and consenting patient
- Patient physically and mentally capable of completing the post-operative pain assessment self-questionnaire
- Patient having signed the informed consent of the French Ophthalmology Society for crosslinking
- Patient affiliated to a social security system or beneficiary of such a system
Who cannot take part
- Patient on long-term analgesics and/or corticosteroids
- Patient treated with topical cyclosporine in the last 6 months
- Patient with a history of refractive surgery on one of the eyes
- Patient suffering from a serious systemic pathology (autoimmune and/or immunodepressive)
- Patient with a psychiatric pathology
- Patient suffering from a severe dry eye syndrome or a neurotrophic keratitis
- Patient with a history of ocular herpes
- Patient with a history of ocular varicella-zoster virus infection
- Woman without effective means of contraception, pregnant or breastfeeding
- Patient who has already benefited from a crosslinking procedure on one of the eyes
- Patient with an intracorneal ring segment on one of the eyes
- Indication of crosslinking outside the classic protocol
- Patient with central corneal opacity
- Patient with glaucoma
- Patient deprived of liberty by a judicial or administrative decision
- Patient subject to a legal protection measure or unable to express their consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties.
Read full original descriptionShow less
The objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.
The 2 groups in the trial
- Therapeutic lens aloneExisting treatment, for comparison
- Therapeutic lens + amniotic membrane (Visio-AMTRIX)Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter, Randomized Study Evaluating the Use of a Non-sutured Sterile Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
- Plain-language title
- Amniotic membrane placed on the eye after crosslinking for progressive keratoconusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06450470, who can take part
- Record updated
- 11 April 2025